Ezabenlimab
- Generic Name
- Ezabenlimab
- Drug Type
- Biotech
- CAS Number
- 2249882-54-8
- Unique Ingredient Identifier
- 5V1UI86573
Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours
- Conditions
- Neoplasm Metastasis
- Interventions
- First Posted Date
- 2018-10-05
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 212
- Registration Number
- NCT03697304
- Locations
- 🇺🇸
Florida Cancer Specialists-Fort Myers-52980, Fort Myers, Florida, United States
🇺🇸Florida Cancer Specialists-Saint Petersburg-52979, Saint Petersburg, Florida, United States
🇺🇸Florida Cancer Specialists-Sarasota-61670, Tallahassee, Florida, United States
A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours
- Conditions
- NeoplasmsNon-squamous, Non-Small-Cell Lung Cancer
- Interventions
- First Posted Date
- 2018-03-16
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 252
- Registration Number
- NCT03468426
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Beverly Hills Cancer Center, Beverly Hills, California, United States
🇺🇸Winship Cancer Institute, Atlanta, Georgia, United States
This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer
- First Posted Date
- 2018-02-15
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 146
- Registration Number
- NCT03433898
- Locations
- 🇯🇵
Kanagawa Cancer Center, Kanagawa, Yokohama, Japan
🇯🇵Japanese Foundation for Cancer Research, Tokyo, Koto-ku, Japan
🇯🇵National Cancer Center Hospital East, Chiba, Kashiwa, Japan
Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma
- Conditions
- Glioblastoma
- Interventions
- Biological: NK-92/5.28.z
- First Posted Date
- 2017-12-27
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Johann Wolfgang Goethe University Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT03383978
- Locations
- 🇩🇪
Johann W. Goethe University Hospital, Department of Neurosurgery, Frankfurt, Germany
🇩🇪Johann W. Goethe University Hospital, Senckenberg Institute of Neurooncology, Frankfurt, Germany
🇩🇪Neurochirurgische Klinik, Universitätsmedizin Mainz, Mainz, Rheinland-Pfalz, Germany
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
- Conditions
- NeoplasmsNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2017-05-25
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 62
- Registration Number
- NCT03166631
- Locations
- 🇺🇸
Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.
- Conditions
- Carcinoma, Non-Small-Cell LungNeoplasms
- Interventions
- First Posted Date
- 2017-05-17
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 172
- Registration Number
- NCT03156114
- Locations
- 🇪🇸
Hospital Universitari Dexeus, Barcelona, Spain
🇪🇸Hospital Politècnic La Fe, Valencia, Spain
🇬🇧Sarah Cannon Research Institute, London, United Kingdom
A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 112
- Registration Number
- NCT02952248
- Locations
- 🇨🇦
The Ottawa Hospital, Ottawa, Ontario, Canada
🇨🇦Juravinski Cancer Centre - Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.